Can Interferon Therapy Change the Natural Course of Hepatitis Delta Infection?: a Clinical and Pathological Study-Reference-Cited by-同舟云学术

Can Interferon Therapy Change the Natural Course of Hepatitis Delta Infection?: a Clinical and Pathological Study

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Bakkaloglu Oguz Kagan¹^ORCID,Yildirim Ozgen²,Cavus Bilger³,Evirgen Sami⁴,Gokturk Suut⁵,Ormeci Asli³,Soyer Ozlem⁶,Akyuz Filiz³,Demir Kadir³,Kaymakoglu Sabahattin³,Gulluoglu Mine⁷,Karaca Cetin³

Affiliation:

1. Istanbul University—Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Section of Gastroenterology, Istanbul, Turkey

2. Diyarbakir State Hospital, Diyarbakir, Turkey

3. Istanbul University, Istanbul Medical School, Department of Internal Medicine, Section of Gastroenterology, Istanbul, Turkey

4. University of Health Sciences, Kastamonu State Hospital, Kastamonu, Turkey

5. Saint Mary’s Hospital, Waterbury, Connecticut, USA

6. Medicana International Hospital, Istanbul, Turkey

7. Istanbul University, Istanbul Medical School, Department of Pathology, Istanbul, Turkey

Abstract

Chronic delta hepatitis (CDH) has a worse outcome than other types of viral hepatitis. High-dose, long-term alpha interferon (IFN-α) is the approved treatment and may ameliorate the course of infection.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01586-21

Reference37 articles.

1. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers.

2. Decrease in HDV endemicity in Italy

3. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies;Degertekin H;Turk J Gastroenterol,2006

4. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B

5. A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma